When a diagnosis arrivesdecides what it is worth.
In a neonatal intensive care unit, a genetic diagnosis has a window in which it can still change treatment. Sixteen hours of compute plus queue time plus interpretation can fall outside it.
01 · Why time matters clinically
The same computation, a different unit of value.
A research laboratory measures analysis in dollars. A clinical laboratory measures it in whether the result is actionable when it arrives. Rapid whole-genome sequencing in critical care is the clearest case: the clinical question is not whether a diagnosis is possible but whether it lands inside the treatment window.
That is why one engine serves two markets with very different willingness to pay, and why the clinical tier carries a priority queue and on-demand capacity rather than shared best-effort compute.
02 · What gates clinical use
Certification, stated precisely.
In the United States, CLIA certification is held by the laboratory that reports a clinical result — it is not a property of the software it uses. GenoAccel's role is to support a certified laboratory's compliance with versioned pipelines, immutable results, audit trails and validation evidence its inspection will ask for.
On 31 March 2025 a federal court vacated the FDA's laboratory-developed-test rule, holding that such tests are professional medical services regulated by CMS under CLIA rather than devices regulated by the FDA. FDA implemented the vacatur on 19 September 2025. The practical effect is that CLIA, not FDA clearance, is the operative gate.
We state this plainly because vendors in this space routinely imply clearances they do not have. GenoAccel is not an FDA-cleared in vitro diagnostic device, and it does not replace a laboratory's certification.
03 · Available today
Research and pre-clinical, not diagnostic.
| Capability | State |
|---|---|
| Research and method development | In place |
| AWS BAA and HIPAA-eligible service scope | In place |
| Audit trail and immutable analysis records | In place |
| SOC 2 Type II report | Roadmap |
| CLIA / CAP certification | Roadmap |
| ACMG classification and clinical sign-out | Roadmap |
If you are a CLIA-certified laboratory evaluating GenoAccel as an analysis vendor rather than as a reporting laboratory, that conversation can start now — the validation and audit evidence your inspection needs is exactly what the platform is built to produce.